Advances in treatment for cytomegalovirus retinitis.
Malcolm B. Bowers
Abstract
Malcolm B. Bowers
Abstract
Advances in ganciclovir and foscarnet therapies for treating cytomegalovirus retinitis, including ocular implants and injections, alternating use of foscarnet and ganciclovir, oral ganciclovir use, cidofovir treatment, and injecting either ganciclovir or foscarnet directly into affected eyes, are discussed. Interactions and adverse side effects for both drugs are listed. Final comments discuss efforts made by Isis Pharmaceuticals and their clinical testing of an antisense drug for CMV.
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Advances in ganciclovir and foscarnet therapies for treating cytomegalovirus retinitis, including ocular implants and injections, alternating use of foscarnet and ganciclovir, oral ganciclovir use, cidofovir treatment, and injecting either ganciclovir or foscarnet directly into affected eyes, are discussed. Interactions and adverse side effects for both drugs are listed. Final comments discuss efforts made by Isis Pharmaceuticals and their clinical testing of an antisense drug for CMV.
Key concepts: Foscarnet, Ganciclovir, Cidofovir, Retinitis, Cytomegalovirus retinitis, Medicine, Cytomegalovirus, Virology